Affirmed Therapeutics BV (NASDAQ:AFMD) shares traded down 6% during mid-day trading on Tuesday . The company traded as low as $2.68 and last traded at $2.68, with a volume of 52,012 shares changing hands. The stock had previously closed at $2.85.

AFMD has been the subject of a number of analyst reports. Leerink Swann upgraded shares of Affirmed Therapeutics BV from a “market perform” rating to an “outperform” rating in a research report on Monday. Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Jefferies Group decreased their price objective on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, May 19th. Finally, BMO Capital Markets initiated coverage on shares of Affirmed Therapeutics BV in a research report on Monday, April 11th. They issued an “outperform” rating and a $7.00 price objective for the company. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $9.46.

The company’s market capitalization is $98.83 million. The firm has a 50-day moving average of $3.02 and a 200-day moving average of $3.62.

Affirmed Therapeutics BV (NASDAQ:AFMD) last issued its quarterly earnings data on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.08. The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.88 million. The company’s quarterly revenue was down 24.0% compared to the same quarter last year. Analysts forecast that Affirmed Therapeutics BV will post ($0.95) earnings per share for the current year.

A hedge fund recently raised its stake in Affirmed Therapeutics BV stock. Tekla Capital Management LLC raised its stake in Affirmed Therapeutics BV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 294,213 shares of the biopharmaceutical company’s stock after buying an additional 66,130 shares during the period. Tekla Capital Management LLC owned 0.97% of Affirmed Therapeutics BV worth $2,095,000 as of its most recent filing with the SEC.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.